NEW YORK (GenomeWeb) – Signal Genetics raised the target amount from its proposed initial public offering to up to $12.1 million.

In an amended Form S-1 filed with the US Securities and Exchange Commission on Friday, the company said it plans to offer 1.15 million shares of its common stock in its IPO at a range of $10 to $12 per share. At the midrange price of $11 the offering would bring in net proceeds of $10.3 million. If the underwriters exercise their overallotment option in full, that figure would rise to $12.1 million.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Researchers report using genotyping to tie together illegal ivory shipments and trace them back to a handful of cartels, the New York Times reports.

Researchers find that historical factors influence which genes are the most highly studied, the Atlantic reports.

The US National Science Foundation's new sexual harassment policy is to go into effect next month, according to Nature News.

In Nature this week: genomic ancestry analysis of Sardinians, current noncoding mutations in colorectal cancer, and more.

Oct
17
Sponsored by
Lexogen

This webinar will present a method for RNA-seq expression analysis of FFPE-derived RNA samples that are too degraded for successful application of standard RNA-seq techniques.

Oct
25
Sponsored by
Roche

This webinar will detail a comprehensive strategy that a lab has put in place to evaluate  NGS oncology assays for genomic tumor profiling of plasma and tissue samples.